Arthur Kavanaugh, MD

Arthur Kavanaugh, MD


Arthur Kavanaugh MD, is currently Professor of Medicine at the University of California, San Diego (UCSD) School of Medicine. In addition, he is the Director of the Center for Innovative Therapy in the UCSD Division of Rheumatology, Allergy, and Immunology.

Dr. Kavanaugh earned his BS in biology at the Massachusetts Institute of Technology in Cambridge, Massachusetts and his MD at Saint Louis University School of Medicine in Saint Louis, Missouri. He completed a residency in Internal Medicine and then a fellowship in Clinical Immunology/Allergy at the Baylor College of Medicine in Houston Texas. Dr Kavanaugh also completed a Rheumatology fellowship at the University of Texas Southwestern Medical School in Dallas. He subsequently spent more than a decade on the faculty at UTSWMC before joining the Rheumatology, Allergy, Immunology Division at UCSD, where he has been since 1999.

Dr. Kavanaugh has authored more than 300 peer reviewed scientific publications and reviews and book chapters. He is on the editorial board for several journals and has served as peer reviewer for more than a dozen scientific journals. Dr Kavanaugh is a fellow of the American Academy of Allergy, Asthma, and Immunology (AAAAI), and the American College of Rheumatology (ACR). He has been a member of and chaired a number of committees in these organizations.

Dr Kavanaugh’s main research interest has been in clinical research, particularly translational aspects of rheumatology research. This has included work delineating the pathophysiology of rheumatic diseases as well as defining changes associated with novel immunomodulatory therapies. The focus of many clinical projects has been rheumatoid arthritis and psoriatic arthritis, but Dr Kavanaugh has conducted many studies in other autoimmune conditions, including systemic lupus erythematosus, ankylosing spondylitis, inflammatory bowel disease, and others. In addition, he has performed studies focusing on novel imaging methods and also clinical outcomes. Dr Kavanaugh has been involved with helping to create guidelines for the treatment and optimal care of patients with rheumatic diseases. Dr Kavanaugh was involved with the formation of GRAPPA (group for research and assessment of psoriasis and psoriatic arthritis) and remains on the steering committee. He has been a board member of CORRONA (consortium of rheumatology researchers of north America) since its inception.


  1. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven R. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2009;61:1592-1600. PMID: 19877104
  2. Kavanaugh A, Lee SJ, Weng HH, Chon Y, Huang XY, Lin SL. Patient derived joint counts are a potential alternative for determining disease activity score. J Rheumatol 2010;37:1035-41 (Epub 2010 Feb 15). PMID: 20156946
  3. Kavanaugh A, Keystone E, Feng JY, Hooper M. Is a 12-week trial sufficient to evaluate clinical responses to etanercept or MTX treatment in early RA? Rheumatology (Oxford). 2010;49:1201-3 (Epub 2010 Feb 24]. PMID: 20181672
  4. Weinbaltt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12 (Epub 2010 Sep 22). PMID: 20879879
  5. Ceponis A, Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28 (Suppl 61):S132-7. PMID: 21044447
  6. Rosengren S, Wei N, Kalunian K, Kavanaugh A, Boyle D.  CXCL13: a novel biomarker of B cell return following rituximab tratment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). Epub 2010 Nov 23. PMID: 21098574
Bookmark and Share